Approval · Notice of Compliance 16353 · 2014
ACT OXYCODONE CR: Notice of Compliance 16353
Issued November 24, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16353
- Date
- November 24, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph and labels
- Therapeutic class
- Opioid analgesic
- Canadian reference product
- OXYCONTIN (Purdue Pharma)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT OXYCODONE CR | 02394170 | Cancelled Post Market |
| ACT OXYCODONE CR | 02394189 | Cancelled Post Market |
| ACT OXYCODONE CR | 02394197 | Cancelled Post Market |
| ACT OXYCODONE CR | 02394200 | Cancelled Post Market |
| ACT OXYCODONE CR | 02394219 | Cancelled Post Market |
Medicinal ingredients
- OXYCODONE HYDROCHLORIDE 5 MG per TAB
- OXYCODONE HYDROCHLORIDE 10 MG per TAB
- OXYCODONE HYDROCHLORIDE 20 MG per TAB
- OXYCODONE HYDROCHLORIDE 40 MG per TAB
- OXYCODONE HYDROCHLORIDE 80 MG per TAB